Market Cap: $282.49M
AI
Agenus Inc.
AGEN
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $282.49M
Agenus Responds to Emerging Trends in the Biopharmaceutical Landscape Agenus continues to position itself at the forefront of immuno-oncology, driven by innovative therapies aimed at improving treatme…
Agenus Partners with Zydus Lifesciences to Strengthen Biologics Manufacturing Capabilities Agenus Inc. solidifies its strategic positioning in the biopharmaceutical sector through a significant partne…
Agenus: Pioneering Immuno-Oncology Developments Amid Market Dynamics Agenus, a leading biotechnology company focused on immuno-oncology, continues to make significant strides in its research and devel…
Agenus Advances Immunotherapy Pipeline with New Clinical Trial Initiatives Agenus, a biotechnology firm specializing in immunotherapy, announces significant developments in its clinical pipeline, part…
Agenus Advances in Immuno-Oncology with Upcoming Earnings Report Agenus Inc., a key player in the biopharmaceutical sector, is gearing up to release its quarterly earnings report on August 11, 2025. T…
Zydus Lifesciences Expands Biologics Footprint with Acquisition of Agenus Facilities In a significant strategic move, Zydus Lifesciences Ltd. announces its acquisition of Agenus Inc.'s biologics contr…
Zydus Lifesciences Enters Biologics CDMO Sector with Acquisition of Agenus Facilities Zydus Lifesciences Ltd. makes a significant advancement into the biologics contract development and manufacturing…
Innovating Vaccine Production: SaponiQx's Breakthrough with cpcQS-21 SaponiQx, a subsidiary of Agenus Inc., announces a pivotal advancement in vaccine adjuvant technology with the publication of precl…
Advancing Vaccine Development: SaponiQx Collaborates to Innovate Adjuvants SaponiQx, a subsidiary of Agenus Inc., is making significant strides in vaccine development through a strategic collaboration…
Agenus Subsidiary Partners to Enhance Vaccine Adjuvant Development Agenus Inc.'s subsidiary, SaponiQx, is making significant strides in the field of vaccine adjuvants through a newly announced strateg…
A New Era in Cancer Care: Agenus and Tanner Pharma Join Forces Agenus, an innovator in immuno-oncology, collaborates with Tanner Pharma to enhance patient access to investigational therapies botensili…
Agenus Realigns Strategy to Enhance Financial Stability and Focus on Immuno-Oncology Agenus Inc., a prominent immuno-oncology firm based in Lexington, Massachusetts, undertakes a strategic realignment…
Agenus Secures Funding to Enhance Immuno-Oncology Pipeline Agenus Inc., a Lexington-based immuno-oncology company, successfully closes a $22 million non-amortizing mortgage backed by its biomanufactur…
Agenus Advances Immunotherapy Research with Promising New Data Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunotherapeutic agents for cancer treatment, makes significant strides in its…
Agenus Prepares for Q3 Financial Results Amidst Innovative Oncology Advancements Agenus Inc., an influential player in the immuno-oncology sector, is set to release its financial results for the third…
Agenus Advances in Immuno-Oncology with Upcoming Financial Report Agenus Inc., a leading player in the immuno-oncology sector, is poised to release its third-quarter financial results for 2024 on Nove…